Patients with type 2 diabetes who received intravitreal anti-vascular endothelial growth factor (VEGF) injections for diabetic retinopathy were more likely to develop systemic adverse events (AEs) ...

The use of anti-vascular endothelial growth factor injections has been linked to an increased risk of mortality in patients with diabetic retinopathy in a new study, sounding a note of caution ...

A four-year clinical study has found that while early treatment of diabetes-related eye disease using anti-vascular endothelial growth factor (anti-VEGF; aflibercept) slowed progression to severe ...

Anti-vascular endothelial growth factor (anti-VEGF) drugs can substantially decrease the risk of vision loss from diabetic retinopathy. However, eye care providers have been unsure when treatment ...

Although corticosteroids were found to immediately improve best-corrected visual acuity and central macular thickness, anti–vascular endothelial growth factor (anti-VEGF) therapies had significant ...

Please provide your email address to receive an email when new articles are posted on . Mynampati and colleagues measured VEGF levels in 59 eyes of patients with diabetic retinopathy (DR) who had ...

Eye injections are the only medication currently available to treat diabetes-related retinopathy. Modern eye injections are not painful and don’t cause many side effects. Diabetic retinopathy affects ...

In patients with proliferative diabetic retinopathy, treatment with anti–vascular endothelial growth factor (anti-VEGF) may offer a safer alternative to panretinal photocoagulation (PRP), leading to ...

Please provide your email address to receive an email when new articles are posted on . KIAWAH ISLAND, S.C. — In this Healio Video Perspective from Kiawah Eye, Joe Luvisi, MD, discusses the use of AI ...

A presentation during the recent American Society of Retina Specialists (ASRS) annual meeting confirmed a recent report linking anti-vascular endothelial growth factor (VEGF) drugs to an increased ...